GT Biopharma appoints new director, amends equity facility to raise up to $20M

GT Biopharma, Inc.

Andrew Ritter resigned from board effective June 9, 2025.
David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.
Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.
Equity facility remains at $20M; change gives more flexibility for future stock sales.

item 1.01item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David C. Mun-Gavin

Non-employee Director and Chair of the Compensation Committee

GTBP · GT Biopharma, Inc.

Effective: 2025-06-10
Filed: Jun 11, 2025 23:59 UTC

On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.

Departed

Andrew Ritter

Member of the Board of Directors

GTBP · GT Biopharma, Inc.

Effective: 2025-06-09
Filed: Jun 11, 2025 23:59 UTC

On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.

Source: SEC EDGAR

accession 0001641172-25-014700

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.